Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

94.96 +3.74 (+4.10%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

October 17, 2025

From AstraZeneca

Via Business Wire

Invo Fertility Stock Is Plunging After White House Announcement ↗

October 17, 2025

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

Via Benzinga

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

October 17, 2025

From AstraZeneca

Via Business Wire

AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump ↗

October 10, 2025

Via Stocktwits

AstraZeneca Announces $4.5B Investment In Virginia ↗

October 09, 2025

Via Stocktwits

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

October 17, 2025

From AstraZeneca

Via Business Wire

UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report ↗

October 16, 2025

UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing.

Via Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗

October 16, 2025

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Via Benzinga

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades ↗

October 16, 2025

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

Via The Motley Fool

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs ↗

October 15, 2025

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.

Via Benzinga

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug ↗

October 15, 2025

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma.

Via Stocktwits

AstraZeneca unveils expanded manufacturing facility in Texas

October 15, 2025

From AstraZeneca

Via Business Wire

AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment ↗

October 15, 2025

Discover AstraZeneca, a top-quality stock with strong growth, high ROIC, and robust cash flow. A prime candidate for long-term investors seeking durable competitive advantages.

Via Chartmill

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.

Via Benzinga

Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?

October 13, 2025

Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to...

Via MarketMinute

Topics Artificial Intelligence

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

October 13, 2025

From AstraZeneca

Via Business Wire

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans ↗

October 10, 2025

Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model.

Via Benzinga

Topics Government

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments ↗

October 10, 2025

UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.

Via Benzinga

Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Economy Intellectual Property Retirement

AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs ↗

October 09, 2025

AstraZeneca will invest $4.5 billion in a Virginia facility, creating 3,600 jobs and producing advanced cancer and metabolic medicines using AI and automation.

Via Benzinga

Topics Artificial Intelligence

Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗

October 09, 2025

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

Via Benzinga

Topics Government

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

October 09, 2025

From AstraZeneca

Via Business Wire

A Look Into AstraZeneca Inc's Price Over Earnings ↗

October 09, 2025

Via Benzinga

Should You Forget Nvidia and Buy These 2 Millionaire-Maker Stocks Instead? ↗

October 09, 2025

These two up-and-coming tech stocks just might make investors more money over the next decade than Nvidia will.

Via The Motley Fool

Topics Artificial Intelligence

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

AstraZeneca's Baxdrostat Shows Meaningful Blood Pressure Control In Patients With Resistant Hypertension ↗

October 07, 2025

AstraZeneca's Baxdrostat cut 24-hour systolic blood pressure in a Phase 3 trial, showing promise for treatment-resistant hypertension patients.

Via Benzinga

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

October 07, 2025

From AstraZeneca

Via Business Wire

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices ↗

October 06, 2025

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions.

Via Benzinga

Topics Government

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases ↗

October 06, 2025

Algen Biotechnologies partners with AstraZeneca in a $555 million deal to advance AI-driven CRISPR drug discovery and novel immunology therapies.

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.